Power calculation at a constant sample size of 490, allowing for varying percentage declines in creatinine clearance (CrCl) estimates in the TAF implant and TDF/FTC oral groups
| Mean CrCl % decline in TDF/FTC group | ||||||
| 3 | 4 | 5 | 6 | 7 | ||
| Mean CrCl % decline in the TAF group | 0.5 | 56 | 84 | >95 | >95 | >95 |
| 1 | 39 | 72 | 90 | >95 | >95 | |
| 1.5 | 24 | 56 | 84 | >95 | >95 | |
TAF, tenofovir alafenamide; TDF/FTC, tenofovir disoproxil fumarate and emtricitabine.